Related Experiment Videos
Immunosuppressant switching between cyclosporine and tacrolimus after liver transplantation
Y Hashikura1, S Kawasaki, H Matsunami
1First Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
Transplantation Proceedings
|April 1, 1996
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Genetic variation across the human olfactory receptor repertoire alters odor perception.
Proceedings of the National Academy of Sciences of the United States of America·2019
Agonists of G-Protein-Coupled Odorant Receptors Are Predicted from Chemical Features.
The journal of physical chemistry letters·2018
Transient receptor potential (TRP) channels and taste sensation.
Journal of dental research·2009
Purification and characterization of 3-isopropylmalate dehydrogenase from Thiobacillus thiooxidans.
Journal of bioscience and bioengineering·2005
Exploration on Life Education in Deceased Organ Donation in China.
Transplantation proceedings·2026
Evaluation of CYP3A Phenoconversion in Immunosuppressed Patients Following Kidney Transplantation.
Transplantation proceedings·2026
Short and Long-Term Results of Kidney Transplantation From Extended Criteria Donors.
Transplantation proceedings·2026
Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".
Current oncology (Toronto, Ont.)·2026
Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.
Current oncology (Toronto, Ont.)·2026
[177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.
Current oncology (Toronto, Ont.)·2026
A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.
Current oncology (Toronto, Ont.)·2026